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This is a personal account of the
development of the treatment of end stage
renal disease (ESRD)† at Yale by
hemodialysis and transplantation between
1967 and 1985. These modalities became
available after 1960 and were the first
definitive treatments for kidney failure.
During the ensuing 40 years, they became
the standard and most effective treatment
for ESRD. Today, a renal transplant pro-
vides the best option for a patient with
renal failure, and dialysis is used to keep
the patient alive until a suitable kidney
becomes available or for the long term
treatment of those individuals who are
unwilling or unable, for medical reasons,
to undergo the surgery and immunosup-
pressive therapy.
Kidney disease was first recognized
by its clinical manifestations. Dropsy —
the accumulation of fluid in the body tis-
sues leading to swelling of the extremities,
rapid weight gain, and diminished urinary
output — was thought to represent failure
of the kidneys, although in many instances
the problem was primarily cardiac failure.
Richard Bright, a physician at Guy’s hospi-
tal in the early part of the 19th century, was
the first to distinguish between dropsy of
renal origin and other causes by its patho-
logical and laboratory findings, the visible
changes in the kidneys at autopsy and albu-
min in the urine. Bright’s disease became
the generic name for all types of nephritis
until these were later classified into the
various types according to the distinctive
pathological findings in the kidneys. There
was no effective treatment, and the disease
generally progressed to renal failure and
death from uremia. Early in the 20th centu-
ry, renal disease became more defined by
its physiological manifestations and loss of
homeostasis with fluid retention, elec-
trolyte changes, loss of acid base balance,
and the accumulation of nitrogenous waste
products. Treatment was directed at these
problems by the use of diuretics, chemical
correction of electrolyte changes and
dietary protein restriction. These measures
were partially successful in decreasing
morbidity and prolonging life, but with the
advent of total renal failure, little could be
done. The end of the 20th century ushered
in a new era.
In 1938 at the University of
Gruningen in Holland, a young intern, Dr.
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New Haven, ConnecticutWillem Kolff, faced with a young patient
dying of kidney failure, began experiment-
ing with a sausage casing of cellophane
and heparin, a newly discovered chemical
that prevented blood clotting. He placed
blood that had been anticoagulated, con-
taining a high concentration of urea, in the
sausage casing and immersed it in a saline
bath. He found that the urea passed rapid-
ly out of the cellophane casing into the
bath of saline, thus cleansing the blood by
dialysis. Shortly afterward, the German
armies marched into Holland, and Dr.
Kolff continued working as a staff doctor
in a civilian hospital under the occupation.
He performed the first dialysis on a patient
using this principle in 1943 [1]. He wound
the cellophane tubing, through which he
ran the patient’s blood, around a drum that
rotated in a bath of dialysate fluid.
Unfortunately, of the first 15 patients he
treated, only one survived. After the war,
Dr. Kolff visited the Peter Bent Brigham
Hospital in Boston, and as a result, a group
under Drs. John Merrill and Carl Walter
developed the Kolff-Brigham kidney. By
1950, they began to successfully treat
patients with acute and chronic renal fail-
ure by hemodialysis. This was an essential
prelude to the development of kidney
transplantation as it provided a method to
maintain patients with kidney failure
while they awaited the availability of a
suitable kidney. During World War II, in
Glasgow, Scotland, Drs. Thomas Gibson
and Peter Medawar were studying the
problem of the rejections of skin grafts in
burn patients [2]. Extensive burns had
become a major problem for many Royal
Air Force pilots and aircrews who sur-
vived plane crashes. Their work proved to
be the beginning of the modern era of
transplantation immunology. Some 10
years later, in 1959, Rupert Billingham,
Leslie Brent, and Peter Medawar, present-
ed their landmark experiments on
immunologic tolerance to skin homografts
in mice at a faculty seminar at University
College London, where I was teaching
anatomy. They showed that the injection
of lymphocytes derived from one strain of
mice into another strain of fetal mice in
utero made these mice, when born, toler-
ant to skin grafts derived from the mice
that had donated the lymphocytes [3].
The interest in transplantation goes
back to at least the 15th century. A paint-
ing by Fra Angelico in the Museo di San
Marco in Florence depicts the saints
Cosmas and Damian (who were early
Christian martyrs) replacing a devoted
church member’s leg that had been afflict-
ed by a malignancy with the leg of an
African slave.
The graft was said to have been suc-
cessful, probably because they were
blessed by divine assistance.* John Hunter,
the experimental English surgeon in the
18th century, believed transplanted tissue
would live and claims to have successfully
transplanted a cock’s testis to a hen, appar-
ently without affecting the disposition of
the hen. In 1902, Ernest Ullman in
Germany carried out the first kidney trans-
plants in dogs [4].Afew years later,Alexis
Carrel showed that autotransplantation, a
kidney from the same animal replaced into
the original animal, could be done success-
fully, but that homotransplantation, a kid-
ney transferred between unrelated animals,
failed within a few days due to a “biologi-
cal problem” [5].
In 1927, Karl Bauer in Germany
showed that skin grafts exchanged
between identical twins could survive
indefinitely [6]. In December 1954, Dr.
Joseph Murray and his colleagues at the
Peter Bent Brigham Hospital in Boston
performed the first successful kidney
transplant between identical twins. About
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* Twin brothers martyred in Syria by the Emperor Diocletian in 287 CE. They were cruci-
fied, stoned, burned, and beheaded. They subsequently became the patron saints of physi-
cians and surgeons.1 in 3 twins is identical and occurs in
about 1 in every 300 births.
The operation was performed at the
suggestion of Dr. David Miller of the U.S.
Public Health Service, who called Dr. John
Merrill at the Peter Bent Brigham Hospital
saying he had a patient with renal failure
due to chronic glomerulonephritis who had
an identical twin and suggested he might
act as a donor. The twin brothers were
brought to the hospital in Boston, and skin
grafts exchanged between them were
found to survive for many weeks. After
further consultation, the transplant was
performed; Dr. Hartwell Harrison removed
the donor kidney, which was implanted in
the recipient by Dr. Joseph Murray. After
one year with the kidney working well, the
operation was reported in the Journal of
the American Medical Association [7].
They performed seven more such trans-
plants during the next four years. Dr.
Murray was later awarded the Nobel Prize
for his pioneering work in transplantation.
The first patient died after eight years due
to development of recurrent glomeru-
lonephritis in the transplanted kidney, a
complication that was subsequently found
to occur in about 50 percent of recipients,
after transplantation between identical
twins whose kidneys had been initially
destroyed by glomerulonephritis. This
problem occurred less frequently with
transplants from an unrelated donor as the
required use of immunosuppressive agents
tended to prevent the development of the
nephritis.
The modern era of organ transplanta-
tion began a few years later in 1959 with
the discovery of a way to suppress the
immune response by Drs. Robert Schwartz
and William Dameshek at Tufts University
Medical School in Boston. They found
that the chemical compound 6-mecaptop-
urine (a purine analog that interferes with
the synthesis of protein that induces the
immune response) could suppress the
immune reaction to a foreign protein
(human serum albumin) injected into rab-
bits [8]. The parent chemical compounds
of 6-mecaptopurine were first synthesized
by George Hitchings and Gertrude Elion at
the Wellcome Laboratories in 1952, when
searching for antimetabolites to treat
leukemia. They later developed azathio-
prine (Imuran), a conjugate of 6-mercap-
topurine, as an immunosuppressive agent,
which was felt to be less toxic [9]. They
were awarded the Nobel Prize for their
work in 1988. Gertrude Elion visited Yale
as a Tetelman Fellow at Jonathan Edwards
College in 1993.
Dr. Roy Calne, working with Dr.
Joseph Murray, first demonstrated that kid-
ney transplantation between non-identical
animals could be performed successfully
using 6-mercaptopurine to suppress the
immune response to the foreign kidney
[10]. He subsequently became Professor of
Surgery at Cambridge University and a
pioneer in liver transplantation. On his
return to London in 1961, he presented his
work to a surgical research group to which
I belonged and aroused my interest in, and
enthusiasm for, renal transplantation.
The first successful human kidney
transplant from a non-identical donor
using the kidney from a recently deceased
person was performed in 1962 using aza-
thioprine to prevent rejection [11]. The
methodology and dosimetry for these
immunosuppressive agents was worked
out in the dog model prior to its clinical
application and is one of the prime exam-
ples of the value and importance of animal
experimentation in the development and
establishment of boundary-breaking clini-
cal treatments. The administration of large
doses of cortisone to supplement the
immunosuppressive effects of Imuran was
introduced at that time by the Brigham
group.
I came to Yale in 1962 as an assistant
professor in Urology and continued some
of my work in tumor immunology that I
had begun as a British Empire Cancer
Fellow at Kings College Hospital in
London. Cancer poses the obverse prob-
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tumor is not rejected when it exhibits pro-
teins different from those expressed by the
host. We had been able to show that the
injection of human tumor extracts into the
host could elicit an immune response in
the form of a delayed hypersensitivity
reaction. I also acquired some experience
in the technique of kidney transplantation
in a study of the vesicorenal reflex in dogs.
This required a complete denervation of
the kidneys, accomplished by bilateral
renal auto transplantation. The initiation of
the renal transplantation program had to
wait until 1966 when Dr. Jack Cole was
appointed as the new chief of surgery. He
was committed to a program of organ
transplantation and made available the
necessary resources and created the favor-
able political climate needed for the trans-
lation of a new idea into clinical practice.
Thus, in the summer of 1967, Dr.
Howard Levitin in the section of
Nephrology and I began hemodialysis in a
few patients with chronic renal failure as a
prelude to offering them a kidney trans-
plant. Using two machines in a small room
next to his office on the second floor of the
Fitkin building and assisted by Helen
Feigenbaum and another nurse, we carried
out hemodialysis on four patients three
times a week. One of the problems in
chronic hemodialysis is the need for
repeated vascular access. At first we
inserted silastic arteriovenous shunts
between the radial artery and vein that had
been designed by Dr. Belding Scribner in
Seattle, Washington. These shunts clotted
frequently and occasionally became
infected. We soon adapted a new idea to
our own use in which we anastomosed the
radial artery to the adjoining vein. This
increases the pressure and flow in the
veins of the arm so they become distended
and can be readily accessed for hemodial-
ysis [12, 13].
In the treatment of chronic kidney
failure, I have always considered dialysis a
holding action in preparation for a kidney
transplant as the definitive treatment. Our
first patient, who urgently needed a kidney
transplant, was a 52-year old Polish immi-
grant who served in World War II as a
fighter pilot with the Royal Air Force. He
developed renal failure secondary to
chronic glomerulo-nephritis. He had a dif-
ficult time on dialysis, as he found the
fluid and salt restriction very hard to toler-
ate. On December 9, 1967, three Yale stu-
dents were traveling south in a car on
Interstate 95 near Exit 10 when the dri-
ver’s vision was temporarily obscured by
smoke from an old incinerator at the side
of the road. They lost control of the car,
and one of the passengers sustained a
severe head injury. On the morning of
December 21, it became apparent he had
no brain function, and a small committee
was convened that had been previously set
up by Chief of Staff Dr. Lawrence Pickett
to decide whether a person could be
declared brain dead while on a life-support
system. The committee concluded that the
patient had no cerebral function, and per-
mission to remove the kidneys for trans-
plantation was obtained from the patient’s
uncle, who was a physician. The patient’s
respirator was turned off, and the intended
recipient of the kidney was brought to the
operating room.
As we prepared to carry out removal
of the kidneys from the donor, I was called
to the telephone. It was the president of the
hospital, who asked me in an angry voice,
“What in the hell are you doing?” and
“Who gave you permission to do a trans-
plant in this hospital?” The timing and
content of his remarks seemed inappropri-
ate and so, perhaps impolitely, I hung up
and proceeded to remove both kidneys.
We irrigated the harvested kidneys with a
cold anticoagulant solution and placed
them in a basin of cold irrigant. We then
transferred the left kidney to the operating
room and implanted it in the patient’s
lower abdomen anastomosing the renal
artery end-to-end to the divided internal
iliac artery and the vein to the side of the
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Dr. Cole, the chief of surgery, for moral
support; Dr. Robert Weiss, who is now
Chief of the Urology Service; and two of
the residents at that time, Dr. Martin Schiff
and Dr. John Libertino, who is now Chief
of Urology at the Lahey Clinic. The anes-
thesiologist was Dr. Luke Kitahata, who
had to give the patient K exalate enemas
during the operation to reduce the high
serum potassium.
The procedure fortunately went well,
even though I had never seen one per-
formed in a human before. After complet-
ing the vascular anastomosis in about 20
minutes, we removed the vascular clamps
and were relieved to see the kidney per-
fuse well with blood. My relief was short-
lived, however, as I realized I put the kid-
ney in upside down. Calm was restored
when I remembered from my classes in
physiology that peristalsis is not depen-
dent on gravity. This occurred many times
subsequently and is of no consequence.
The ureter was fortunately long enough so
we were able to implant it into the bladder
without it becoming kinked. The kidney
made urine immediately, and as the patient
left the operating room with 200 cc of
golden-colored liquid in the drainage bag,
I murmured that “happiness today is a lit-
tle urine.” I never lost the thrill of seeing a
patient make urine after receiving a new
kidney often after months or even years of
anuria. This patient, the first kidney trans-
plant in Connecticut, did well, and the
newspapers gave us front-page coverage.
I think the president of the hospital
enjoyed the publicity as he was very com-
plimentary and never mentioned our
phone conversation. The kidney subse-
quently developed acute tubular necrosis
associated with an episode of rejection that
was successfully treated with large doses
of prednisone. After 16 days, the kidney
recovered, his urine output returned to
normal, and he had no further problems.A
year later, he undertook a journey back to
his native Poland for a holiday. On return-
ing to the United States, he described what
a wonderful reception he had received, the
notoriety he achieved as a kidney trans-
plant recipient, still a rare event at that
time, and how he enjoyed all of the previ-
ously proscribed salty foods that are so
popular in his native country. Almost two
years to the day after his operation, he was
re-admitted with severe abdominal pain
and septic shock due to infection and died
within hours from what proved to be a per-
foration of the rectum. This was probably
secondary to a rectal ulcer caused by the
large doses of steroids that he had been
given to prevent rejection. It took several
years for us to learn how to moderate the
dosage of steroids, to minimize the serious
complications that occurred initially both
in the prevention and treatment of
immunological rejection.
The genie was now out of the bottle,
and we were soon engaged in doing many
transplants. We adopted a somewhat dif-
ferent management style for the transplant
program at Yale. The responsibility for the
post-operative care of patients was divided
between the nephrology service, staffed by
two physicians and a nephrology fellow,
and the urology service, staffed by four
surgeons and two residents. While the
nephrologists continued to be the patient’s
doctor of record, the services made joint
rounds each day, and no major changes in
treatment protocols were made without
consultation and consensus. Although this
was a somewhat unique arrangement, it
proved to be very successful because of
the close collaboration of the physicians
concerned. It had the advantage that some-
one was always readily available for emer-
gencies, especially when the urologists
were busy in the operating room, and that
patients who had acute tubular necrosis
postoperatively were dialysed promptly.
Furthermore, their follow-up care as out-
patients was more appropriately carried
out by the nephrologists as many of the
long-term problems in these patients are
primarily medical, such as diabetes, fluid
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plications of prolonged steroid administra-
tion. It also enabled us to continue to func-
tion as a urology service and to provide
adequate training for our residents.
Although we all participated in perform-
ing renal transplants and harvesting kid-
neys, Dr. Martin Schiff had primary
responsibility for the kidney transplants
and the establishment of vascular and peri-
toneal access in patients with chronic renal
failure. There were only four or five cen-
ters in the United States where the urology
service performed the kidney transplants;
the majority were under the direction of
dedicated transplant surgeons in depart-
ments of general surgery. We had good
continuity of care as the same urologic
surgeons, Drs. Lytton, Weiss, McGuire
and Schiff remained in the program for the
first 15 years. There were a few more
changes among the nephrologists; Dr.
Levitin (1967 to 1969) became Dean for
student affairs and was succeeded by Dr.
Robert Brown (1969 to 1972) who then
moved to The Beth Israel in Boston. Dr.
Barry Strauch (1972 to 1973) followed for
one year before going into practice. Dr.
Frederic Finkelstein (1973 to 1978) was
director for five years before taking over
the dialysis service at the Hospital of St.
Raphael and organizing a large home dial-
ysis program. His associate, Dr. Alan
Kliger (1978 to 1985), took over and was
joined by Dr. Peggy Bia (1983 to present),
who succeeded him when he joined Dr.
Finkelstein in private practice.
The results of the next few cases were
not as good as the first; fewer than 50 per-
cent of the kidneys remained functioning
after one year, a little better than the
national average at that time. The sixth
and seventh patients in the summer of
1968 were the first of what we called
“double headers.” That is, we used both
kidneys from a single cadaveric donor for
two recipients. Two young girls, 16 and
14, were the first two recipients from the
same donor.
In the case of the first young woman,
we had to correct her serious metabolic
abnormalities, so the kidney had to be
refrigerated for seven hours after being
perfused with cold Ringer’s lactate solu-
tion following removal from the donor.
There were no perfusion machines at that
time for renal preservation. The young
woman did well, and the kidney survived
for 17 years, after which it failed as a
result of chronic rejection. She has
received a further transplant since and is
now married and has three children. She is
one of the eight early kidney grafts that
survived 15 years and was the only one
with a kidney from a cadaver that did so.
The other young woman lived nine
years and died of a lymphoma. The next
patient, our eighth, was a young girl who
had been our first patient to receive a kid-
ney from a living donor, her mother. It
functioned for six years until it was lost
from chronic rejection. She then received
a second kidney from a cadaver donor. At
that time, a kidney transplant from a
cadaver donor involved a period of six to
24 hours to make the logistical arrange-
ments, harvest the kidneys, and perform
the transplant.
It was a very time consuming and
intensive effort on the part of everyone
concerned. Following a call from an outly-
ing hospital about a possible donor, the
urologic surgeon on call and a junior resi-
dent would drive out to harvest the kid-
neys, collect blood for tissue typing, and
remove a number of lymph nodes to per-
form a mixed lymphocyte reaction test
with the recipients’ lymphocytes that
helped to define the degree of compatibil-
ity. There were always numerous delays
and technical problems to overcome, and
most transplants were performed at night
or in the early hours of the morning. We
did not have satisfactory perfusion
machines for the harvested kidneys during
the first few years, so the transplants were
performed whenever a kidney became
available, which often stretched the
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Eve, we harvested four kidneys, trans-
planted two that evening, and implanted
the other two the following morning.
In 1972, we began to perfuse the har-
vested kidneys to preserve them for up to
48 hours, using a machine designed by Dr.
Folkert Belzer, a former Yale surgery resi-
dent who had moved to San Francisco to
work with Dr. Engelbert Dunphy [14]. A
New England Organ Bank was established
in Boston in 1972 under Dr. Benjamin
Barnes and received kidneys from all over
New England; Dr. Schiff was appointed to
the board to represent Connecticut. The
sera from the donors were typed and
matched against sera from patients on the
waiting lists for a kidney, and the kidneys
were then distributed to the best matched
recipient. Since 1991, kidneys are no
longer preserved by perfusion machines,
but are irrigated with a preserving cold
perfusate which enables them to be kept
refrigerated for up to 36 hours prior to
transplantation.
In April 1972, we performed a living-
related transplant between a pair of 7-year-
old identical twins. Kathleen had lost her
renal function as a result of hemolytic ure-
mia syndrome, and because of their age,
we had to obtain a court order to permit us
to perform the procedure.At that time, this
was the youngest recorded transplant
between identical twins. The psychologi-
cal and ethical issues were reviewed by
Dr. Melvin Lewis, a child psychiatrist, and
debated for some time [15]. The graft is
still functioning, and both young women
are doing well.
Another intriguing problem was the
disproportion between the size of the kid-
ney in relation to the recipient. In 1971, we
transplanted the kidney from a 6-year-old
who died from a motor vehicle accident
into an adult man. Over the next year, the
kidney almost doubled in size and
increased its function steadily during that
time. Two years later, we placed a father’s
kidney into his 3-year-old son, and it filled
half of his abdomen It functioned well but
did not decrease in size. We also trans-
planted the kidneys from an anencephalic
child into an 18-month-old infant, using a
cuff of aorta and vena cava from the donor
to accomplish the vascular anastomoses.
The kidneys functioned well until the child
succumbed to a viral pneumonia after
eight months.
At first, we matched patients only by
their blood groups, but within a few years,
we began tissue-matching using sera from
the recipients blood and lymphocytes har-
vested from the donors lymph nodes in the
case of cadaver donors and peripheral
blood lymphocytes from live donors. We
also tested for direct compatibility
between donor and recipient by the use of
mixed lymphocyte cultures. Cross match-
ing, to detect preformed antibodies to tis-
sue antigens in the recipient, proved to be
very useful as the presence of antibodies
resulted in early rejection in 50 percent of
recipients as compared to 4 percent if they
were absent. Tissue typing was performed
in advance so we could allocate cadaver
kidneys based on the best match.
Matching for two or more histocompati-
bility antigens showed a significant
improvement in graft survival, although a
mismatch did not necessarily predict fail-
ure of the graft. The mixed lymphocyte
reaction, carried out between live donor
and recipient pairs, was more helpful in
that there was a marked improvement in
graft survival when there was less than 20
percent stimulation. Tissue typing began
in 1958, when Dr. Paul Terrasaki from Los
Angeles went to work with Professor Peter
Medawar in London and later with
Professor Jean Dausset in Paris, both of
whom had been involved in defining the
tissue antigens first in the mouse and then
in man. He developed a method to isolate
peripheral white cells from the blood and a
micro test to determine which antigens or
markers they carried, to identify the tissue
type of the patient [16]. Thus began the era
of tissue typing and with it the elaboration
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think Professor Medawar once remarked
that from the immunologist’s viewpoint,
“Man’s best friend is not the dog but the
mouse.”
Many other distinguished immunobi-
ologists contributed to the exciting
research on mapping the histocompatibili-
ty locus on the 6th chromosome. Among
them was Dr. Bernard Amos, an
Englishman working at Duke University.
In 1969, after doing our first transplant, we
developed an immunological advisory
panel that included myself, Dr. Fred
Kantor, and Dr. Malcolm Mitchell.We vis-
ited Duke to learn tissue typing and how to
set up a tissue-typing laboratory at Yale.
We obtained a number of specific sera,
then available both from Dr. Amos and
from a newly created serum bank at the
National Institutes of Health. We were for-
tunate at that time to recruit Dr. Nancy
Ruddle, now a distinguished professor of
immunology at Yale, to help develop and
direct this laboratory, which she continued
to do for the next five years. She was suc-
ceeded by Dr. Marion Zatz for two years
and then by Dr. Robert Cohn (1974 to
1983). After Dr. Cohn left, the laboratory
was taken over by the transplant surgeons,
first by Dr. Wayne Flye and subsequently
by Dr. Marc Lorber.
In 1971, we obtained funding of
$250,000 from the regional medical pro-
gramto promotetransplantationatYale, but
unfortunately the program was canceled for
political reasons after the first year. We also
had a very active program of renal trans-
plantation in children, which was ably
directed for eight to 10 years by two pedi-
atricnephrologists,Drs.NormanSiegeland
Karen Gaudio, who monitored their
patients very carefully and had excellent
graft and patient survivals that were signif-
icantly better than the national averages.
Between 1967 and 1992, the first 25
years, 630 kidney transplants were per-
formed at Yale (Table 1). The number per-
formed each year in the first 15 years aver-
aged only 15 to 20 per year, whereas in the
following 10 years, it averaged 30 to 40
per year (Figure 1). In the early years, we
received no payment for the majority of
cases, because the patients had exhausted
their insurance by the time they came to
transplantation. In 1973, Congress passed
legislation to provide reimbursement for
patients with end-stage renal disease as
part of the Medicare program, a result of
intense lobbying by advocates for patients
with chronic kidney disease and the
nephrologists involved in their care.
There followed a rapid proliferation
of dialysis capability during the next few
years associated with a strong financial
incentive to keep patients on dialysis. This
became known as “the golden age for
nephrologists.” Patients needing dialysis
were rapidly recruited to the program once
there was adequate funding. It became the
conventional wisdom that dialysis was
better and safer than transplantation, and
patients were discouraged from undergo-
ing transplantation. The nurses on the dial-
ysis units developed personal ties with the
patients and would discourage them from
undergoing further treatment based on
anecdotal news of what had happened to
some patients who had undergone trans-
plantation. They did not acknowledge that
patients on dialysis undergo accelerated
degeneration of their blood vessels and
there was a considerable mortality rate,
primarily from heart disease and strokes.
About 50 percent of patients on dialy-
sis died during the first five years. Death
while on dialysis was attributed to “natur-
al causes,” while a death following trans-
plantation was a surgical mortality. We
undertook a study to compare the results in
patients undergoing dialysis with those
undergoing renal transplantation over a
three-year period. It was found that while
survival rates were the same, the quality of
life with a kidney transplant was a great
deal better as judged by the ability to
work, a sense of well being, and sexual
activity [17]. In the early years. not only
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one year, but the patient mortality was
unacceptably high. A review of the first
100 cases indicated that by decreasing the
dose and the length of time of administra-
tion of steroids used for immuno-suppres-
sion and by not persisting in the treatment
for rejection when there were unmistak-
able signs that it was irreversible, patient
mortality and morbidity could be signifi-
cantly reduced without further decreasing
graft survival [18]. Improved methods for
the diagnosis of rejection at an earlier
stage, such as serial nuclear scanning,
devised by Drs. Gerald Freedman and
Martin Schiff, allowed for prompter treat-
ment that also contributed to an improve-
ment in patient survival [19] (Table 2).
Cyclosporin, which was introduced in the
early 1980s, proved to be a much more
effective and less toxic agent for suppress-
ing the immune response. This led to a
dramatic improvement in results; 70 to 80
percent five-year survivals for cadaver
renal grafts and up to 90 percent for living
related donor grafts (Figures 2 and 3).
Thus renal transplantation is now without
a doubt the preferred treatment for chron-
ic renal failure and is widely practiced.
The limiting factor is the availability of
suitable kidney donors, and this has result-
ed in long waiting lists for kidneys in most
transplant centers.
In 1983, Dr. Schiff decided to relin-
quish his position on the transplant service
and Dr. Arthur Baue, then Chief of
Surgery, used this opportunity to recruit a
surgeon dedicated to transplantation to fill
his position as he wished to expand the
program to include other organs. Dr.
Wayne Flye, from Duke University, who
had extensive experience in immunology
and clinical organ transplantation, was
appointed. Dr. Schiff continued to assist
him with the program. By 1983, there was
sufficient dialysis capacity to accommo-
Lytton: Transplantation at Yale 179
Table 1. Transplantation at Yale: 1967-1992.
Cadaver donors 454 (72 percent)
Living related donors 176 (28 percent)
Total 630
Adult 541 (86 percent)
Pediatric 89 (14 percent)
Figure 1. 630 renal transplants at Yale 1967-1992.date all those who needed it. This coupled
with the marked improvement in the
results of renal transplantation following
the introduction of cyclosporin, a more
effective and less toxic immunosuppres-
sive agent, the list of patients awaiting
transplants grew from 20 to 30 patients to
over 90 (Figure 4). The combination of
these factors resulted in a significant
increase in the number of kidney trans-
plants performed each year after 1983.The
limiting factor became the shortage of
suitable kidney donors, and this has
remained a major problem to this day.As a
result there has been a significant increase
in the number of living donors.
In 1983, the first liver transplant was
performed at Yale by Drs. Wayne Flye and
Richard Gusberg. Flye and Schiff flew
down to Florida to harvest the liver. In
November 1984, Drs.Alex Geha and John
Elefteriades performed the first heart
transplant at Yale. Dr. Elefteriades remem-
bers that after harvesting the heart in
Bridgeport, he was returning to Yale in an
ambulance with the heart in a cooler when
the engine failed as a result of excessive
speeding by an overly zealous driver. Dr.
Elefteriades got out and thumbed a ride on
the highway. Fortunately, the car that
stopped for him was a police cruiser that
completed the high-speed journey, with
sirens blaring, to the hospital. The heart
was successfully implanted.
In 1985, Dr. Flye left to become the
head of transplantation at Washington
University in St. Louis, and Dr Marc
Lorber, who trained at the University of
Michigan and Baylor University in
Houston, joined the faculty as chief of the
transplant service. He expanded the pro-
gram of renal and liver transplantation and
in 1987 recruited Dr. William Marks, who
began transplantation of the pancreas in
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Table 2. Mortality after Transplantation (Yale 1968 to 1981).
No. of transplants Deaths Percent
1968-72 84 24 28.6
1973-76 76 11 14.5
1977-81 85 4 4.7
Figure 2. Yale-New Haven organ transplant center, cadaveric renal transplantation
1987 to 1992.diabetic patients with anastomosis of the
duodenum and pancreatic duct to the blad-
der. More recently, Dr. Kevin Anderson
initiated laparoscopic donor nephrectomy
at Yale, with a reduction in morbidity and
hospital stay, so the majority of live
donors are now managed successfully in
this way.
“Life is short, art long, opportunity fleeting,
experience treacherous, judgment difficult.”
Hippocrates
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